[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-arthritis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,55,87,115,142,171,201,224,251,282,312,333,360,388,413,444,469],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100624978","validation-of-hemoglobin-a1c-in-patients-with-inflammatory-arthritis-treated-with-sulfasalazine-100624978",false,"NCT07416656","Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine","How Can We Prevent the Underdiagnosis of Diabetes and the Undertreatment of Known Diabetes in Patients With Inflammatory Arthritis Treated With Sulfasalazine?","DIA2SULFA","Inclusion Criteria:\n\n* Age ≥18 years\n* Treatment with sulfasalazine for at least 2 months prior to inclusion\n* Inflammatory arthritis diagnosis (Reumatoid Arthritis, Reaktive Arthritis, Axial spa, Psoriatic spondylitis, and Juvenil artrit)\n* HbA1c ≥38 mmol\u002Fmol obtained at least 2 months after sulfasalazine initiation OR a diabetes mellitus diagnosis (Type 1 diabetes mellitus, Type 2 diabetes mellitus, Malnutrition-related diabetes mellitus, Other specified diabetes mellitus (andre specificerede former for diabetes), and Unspecified diabetes mellitus (uspecificeret diabetes))\n* Can communicate in Danish\n* Informed consent including permission to upload glucose data and study ID to the Libreview Platform.\n\nExclusion Criteria:\n\n* Systemic treatment or local injections with glucocorticoids within the previous 2 months or planned within the following 4 weeks\n* Clinical conditions interfering with the interpretation of HbA1c expect for sulfasalazine alterations in red cell lifespan (etc. Dapson treatment)\n* Allergy towards the adhesive used in the CGM\n* Considered ineligible for participating (e.g. patients without decision-making capacity, , malignancy, terminal illness, ect.)","ALL","18 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.\n\nThis may lead to underdiagnosis of diabetes in patients who develop diabetes during sulfasalazine treatment, and to undertreatment in patients with known diabetes due to falsely reassuring HbA1c values.\n\nThe study aims to answer two main questions:\n\n1. How many patients treated with sulfasalazine have undiagnosed diabetes despite having HbA1c values below the diagnostic threshold?\n2. Does HbA1c underestimate actual glucose levels when compared with continuous glucose monitoring (CGM) in patients with sulfasalazine-treated inflammatory arthritis, both in those with known diabetes and those that are not diagnosed with diabetes but have borderline HbA1c values (≥ 38 mmol\u002Fmol)?",[25,26,27,28,29],"Inflammatory Arthritis","Diabetes (DM)","Rheumatoid Arthritis (RA)","Type 1 Diabetes Mellitus","Type 2 Diabetes (T2DM)",[31,32,33,34,35,36,37,38,39,40,41],"Validation of HbA1c","Sulfasalazine","Salazopyrin","Continuous glucose monitoring","CGM","Type 2 Diabetes","Diabetes","Hemoglobin A1c","HbA1c","Type 1 Diabetes","Fasting blood glucose","RECRUITING","2026-06-22",{"date":45,"type":46},"2026-06-25","ACTUAL",{"date":48,"type":46},"2026-03-10",{"date":50,"type":21},"2026-10",{"name":52,"class":53},"Klavs Würgler Hansen","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100641054","musculoskeletal-ultrasound-for-differentiating-rheumatoid-and-gouty-arthritis-100641054","NCT07657156","Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis","Role of Musculoskeletal Ultrasound in Differentiation of Rheumatoid Arthritis and Gouty Arthritis Using Semi-Quantitative Scoring","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Either sex.\n* Patients with clinically suspected or confirmed rheumatoid arthritis.\n* Patients with clinically suspected or confirmed gouty arthritis.\n* Patients referred for musculoskeletal ultrasound assessment of painful, swollen, or inflamed joints.\n* Patients able and willing to provide informed consent.\n* Patients whose final diagnosis is established by clinical assessment, laboratory testing, and\u002For relevant imaging or synovial fluid analysis when available.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with septic arthritis or suspected joint infection.\n* Patients with traumatic joint injury involving the target joint.\n* Patients with other inflammatory arthropathies such as psoriatic arthritis, reactive arthritis, or systemic lupus erythematosus if they may confound imaging interpretation.\n* Patients with advanced osteoarthritis in the scanned joint if it markedly limits Faculty of Medicine Institutional Review Board (IRB) Assiut Medical School Research Proposal Form 5 interpretation.\n* Patients with incomplete clinical records or insufficient ultrasound windows.\n* Patients who refuse consent.\n* Patients whose diagnosis remains uncertain after clinical workup.",{"count":63,"type":21},100,"Rheumatoid arthritis (RA) and gouty arthritis (GA) are two common forms of joint inflammation that can present with very similar physical symptoms, making them difficult to tell apart early in the disease process. Accurate and early differentiation is crucial because the treatment strategies and long-term management for the two conditions are substantially different.\n\nThe primary purpose of this observational study is to evaluate the diagnostic performance of musculoskeletal ultrasound (MSUS) in distinguishing between RA and GA. Ultrasound is a safe, radiation-free imaging tool that can visualize joint inflammation and structural changes in real-time. This study utilizes a structured semi-quantitative scoring system (graded on a scale of 0 to 3) to systematically measure the severity of joint lining thickness (synovial hypertrophy) and active blood flow (power Doppler signal). It also checks for crystal-related deposits, such as tophi or the double contour sign, which are highly suggestive of gout.\n\nParticipants aged 18 and older with suspected or confirmed RA or GA who are referred for joint assessment at Assiut University Hospitals will undergo a standard clinical evaluation, routine laboratory testing, and an ultrasound examination of specific target joints (such as the wrists, hands, knees, and ankles). By comparing the ultrasound scores and specific structural findings between the two patient groups, the study aims to establish a reliable, standardized imaging approach to help physicians make faster, more confident diagnoses and initiate the correct disease-specific therapies sooner.",[27,66,67,25],"Gouty Arthritis (GA)","Gout",[69,70,71,72,73,74,75,76],"Musculoskeletal Ultrasound","Semi-quantitative Scoring","Ultrasonography","Synovitis","Power Doppler","Double Contour Sign","Tophi","Diagnostic Imaging","NOT_YET_RECRUITING","2026-06-14",{"date":80,"type":46},"2026-06-18",{"date":82,"type":21},"2026-07",{"date":84,"type":21},"2027-08",{"name":86,"class":53},"Assiut University",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":54},"100614362","the-rheumsafer-study-improving-medication-appropriateness-in-people-with-rheumatic-conditions-100614362","NCT07278609","The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","Inclusion Criteria:\n\n* Aged ≥60\n* Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)\n* Currently taking ≥5 regular medications and ≥1 PIM\n* Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acute life-threatening illness or life expectancy \\\u003C12 months","60 Years",{"count":63,"type":21},"The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).\n\nResearchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:\n\n* MedSafer reports provided to treating physicians\n* EMPOWER consumer brochures provided to participants\n\nParticipants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.",[97,25,98,99,100,101],"Rheumatic Diseases","Systemic Lupus Erthematosus (SLE)","Vasculitis","Muskuloskeletal Diseases","Systemic Autoimmune Diseases",[103,104,97,105],"Deprescribing","Potentially inappropriate medications","Polypharmacy","2026-04-27",{"date":108,"type":46},"2026-05-01",{"date":110,"type":46},"2025-10-29",{"date":112,"type":21},"2028-06-30",{"name":114,"class":53},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100635892","retro-prospective-postmarket-clinical-study-for-fx-shoulder-solutions-shoulder-systems-100635892","NCT07558590","RETRO-PROSPECTIVE POSTMARKET CLINICAL STUDY FOR FX SHOULDER SOLUTIONS SHOULDER SYSTEMS","Inclusion Criteria:\n\n* Indication for hemi or total shoulder replacement with one of the FX SHOULDER SOLUTIONS Shoulder Systems, according to its IFU and surgical technique.\n* Patient aged 18 years and above\n* Patient insured with a social security system\n* Has been informed and did consent to participate to the study.\n\nExclusion Criteria:\n\n* Neurological pathologies compromising the shoulder stability\n* Morbid obesity\n* Muscular deficiencies impairing the shoulder joint",{"count":122,"type":21},1004,"This study takes place in the framework of the PostMarket Clinical Follow-up plan of the Shoulder Systems commercialized by FX SHOULDER SOLUTIONS.\n\nThe included cases will be followed for 10 years after index surgery. Primary objective is the assessment in real life of the revision rate of the shoulder systems at long-term.\n\nSecondary objectives are\n\n* Revision rate at each post op visit\n* Range of motion at each post op visit\n* Quick Dash, Constant, American Shoulder and Elbow Surgeons Shoulder Score (ASES), Subjective Shoulder Value (SSV), Pain scores at each post op visit\n* Radiological assessment of implant positioning through geometrical parameters at each post op visit\n* Incidence of complications at each post op visit\n* Qualitative feedback from surgeons on the instrumentation",[125,126,127,128,129,25,130],"Humeral Fracture, Proximal","Glenohumeral Osteoarthritis","Avascular Necrosis of the Head of Humerus","Rotator Cuff Tear","Rotator Cuff Arthropathy","Revision of a Shoulder Prosthesis","2026-04-24",{"date":133,"type":46},"2026-04-30",{"date":135,"type":46},"2020-06-01",{"date":137,"type":21},"2037-06",{"name":139,"class":140},"FX Solutions","INDUSTRY",22,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":54},"100555914","assessing-central-aspects-of-pain-100555914","NCT06518278","Assessing Central Aspects of Pain","Assessing Central Nervous System Contributions to Accelerate Musculoskeletal Pain Diagnosis and Treatment","AsCent","Inclusion Criteria:\n\n* Adults aged 18 years or over.\n* One for more of the following self-reported diagnoses: fibromyalgia, inflammatory MSK condition (e.g., rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis), low back pain, osteoarthritis.\n* MSK diagnosis and pain onset more than 3 months prior to baseline\n* Self-reported pain levels ≥ 3 on a 0 to 10 numerical rating scale where 0 = 'no pain' and 10 = 'worst pain imaginable' on most days in the 3 months before baseline.\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* Terminal\u002Funcontrolled medical or mental health condition that would prevent participants from completing assessments or pose a significant risk to participants or staff.\n* Insufficient understanding of spoken or written English to comply with the requirements of the study protocol.\n* Inability to adhere to the study protocol.",{"count":151,"type":21},250,"BACKGROUND: Chronic pain continues for more than 12 weeks despite medication or treatment. Chronic pain is the main symptom of muscle and joint problems, rarely explained by damage to the muscle and joints alone. Activity in the central nervous system (CNS; nerves, spinal cord, and brain) pathways governs our ability to describe pain intensity and our emotional response to pain. Musculoskeletal conditions (e.g., inflammatory arthritis, osteoarthritis, low back pain, fibromyalgia) share altered CNS pathways, acknowledged by recent classifications of 'primary' and 'nociplastic' pain. Clinically useful tools to diagnose and measure activity and reveal abnormalities in these CNS pathways are needed to improve clinical decisions and accelerate new treatment development. Laboratory pain sensitivity testing and brain imaging confirm the CNS as a primary contributor to pain. These assessments are less acceptable or unfeasible for clinical practice. Simpler clinical pain sensitivity assessments are being developed. The investigators simple Central Aspects of Pain (CAP) questionnaire detects some people with pain sensitivity and knee, rheumatoid arthritis or low back pain. Combining the CAP questionnaire reflecting emotional processing and simpler pain sensitivity assessment, combining two different dimensions should be better than either approach alone.\n\nPURPOSE: To optimise diagnosis and measurement of CNS as the primary contribution to chronic musculoskeletal pain by using the CAP questionnaire and simpler pain sensitivity assessments to ensure timely, effective diagnosis and treatment.\n\nOBJECTIVES: 1. Assess the ease, ability and performance of the combined CAP questionnaire and simpler pain sensitivity assessments to identify CNS as the primary contributor to chronic pain across musculoskeletal conditions.\n\n2\\. Use the CAP questionnaire alone or with substitute measures of activity in CNS pathways, demographic, and clinical variables to indicate pain levels at six and twelve weeks.\n\n3\\. Understand the relationship between CAP and simpler pain sensitivity assessment with laboratory pain sensitivity assessments as a tool to inform the current CNS activity contributing to pain.\n\n4\\. Evaluate associations between the CAP questionnaire and simpler pain sensitivity assessments with patient outcomes.",[154,155,156,25],"Osteoarthritis","Fibromyalgia","Chronic Low Back Pain",[158,159,160,161,162],"Quantitative Sensory Testing","Temporal Summation","Pressure Pain detection Threshold","Conditioned Pain Modulation","Offset Analgesia","2026-04-02",{"date":165,"type":46},"2026-04-08",{"date":167,"type":46},"2024-10-23",{"date":50,"type":21},{"name":170,"class":53},"University of Nottingham",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100616166","understanding-of-rare-inflammatory-arthritis-in-comparison-to-classical-inflammatory-arthritis--tissular-observations-and-immune-infiltrate-characterization--the-utopic-project-100616166","NCT07302074","Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project","UTOPIC","Inclusion Criteria:\n\n* For all participants:\n\n  * Signed consent form\n  * Patients over 18 years old\n  * Affiliated with a social security scheme\n* For cases:\n\n  * Referred for arthritis or bursitis occurring in the context of a rare systemic autoimmune disease (SAID) or drug-induced toxicity.\n  * Presenting at least one clinical arthritis with synovial thickening confirmed by ultrasound (grade ≥2 in B-mode) and Doppler inflammation of grade ≥1, or synovial thickening ≥B2 associated with joint effusion.\n\nFor bursitis: thickening ≥2mm of at least one periarticular bursa on ultrasound associated with Doppler inflammation of grade ≥1, or synovial thickening ≥2mm associated with joint effusion, with clinical evidence of inflammatory involvement.\n\n\\*For the control group:\n\nFor arthritis:\n\n* Presenting clinical arthritis with synovial thickening confirmed by ultrasound (grade ≥2 in B-mode (B2)) and Doppler inflammation of grade ≥1, or synovial thickening ≥B2 associated with joint effusion.\n* Diagnosed, according to disease-specific classification criteria, with either rheumatoid arthritis (according to ACR\u002FEULAR 2010 criteria), axial or peripheral spondyloarthritis (according to ASAS 2009 criteria), psoriatic arthritis (according to CASPAR criteria), or reactive arthritis based on clinician assessment.\n\nFor bursitis:\n\n* Thickening ≥2mm of at least one periarticular bursa on ultrasound associated with Doppler inflammation of grade ≥1, or synovial thickening ≥2mm associated with joint effusion.\n* Meeting the ACR\u002FEULAR 2012 criteria for polymyalgia rheumatica.\n\nExclusion Criteria:\n\n* For all participants:\n\n  * Patients under protective measures or unable to consent\n  * Pregnant or breastfeeding women\n  * Anticoagulant treatment: vitamin K antagonists (Coumadin, fluindione), direct oral anticoagulants (Eliquis, Pradaxa, Rivaroxaban), heparins at curative doses\n  * Contraindication to local procedure: lymphedema near the joint, chronic wound at the site of the joint, joint prosthesis on the affected joint, corticosteroid infiltration less than 3 months ago at the same site\n  * History of treatment with biotherapy or targeted therapy (JAK inhibitors) within the last 3 months, or within the last 6 months if treated with Rituximab",{"count":63,"type":21},"INTERVENTIONAL",[181],"NA","The pathophysiology of certain inflammatory arthritides remains poorly understood, particularly when associated with rare systemic autoimmune diseases such as systemic sclerosis (SSc), or when emerging in the context of immune-related adverse events from cancer immunotherapies. These immunotherapy-induced arthritides represent a new and increasingly encountered clinical entity in rheumatology. A deeper understanding of the mechanisms underlying joint inflammation in these settings is essential for identifying specific therapeutic targets, especially given the limitations of current treatment options and the risks associated with broad immunosuppressive strategies such as prolonged corticosteroid use, which may impair anti-tumor immune responses.\n\nSynovial biopsy analysis provides a powerful tool for dissecting the cellular and molecular components of joint inflammation, including immune cell infiltration, cytokine profiles, and cell-cell interactions. Advances in high-dimensional techniques such as multiplex immunofluorescence and mass cytometry now allow for the identification and spatial localization of numerous protein markers at the subcellular level. Additionally, spatial transcriptomics offers complementary insight into gene expression profiles within the tissue microenvironment, providing a comprehensive understanding of inflammatory processes.\n\nThe investigators propose a prospective, proof-of-concept study to characterize and compare rare and emerging inflammatory arthritides-including those linked to SSc and immunotherapy-related immune toxicity-with classical inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), polymyalgia rheumatica (PMR), and reactive arthritis. Through detailed immunological and molecular profiling, this study aims to identify disease-specific signatures and novel therapeutic targets. These findings could pave the way for precision medicine approaches and inform the development of targeted therapies in both rare and common forms of inflammatory arthritis.",[25,184,185],"Rare Auto-immune Diseases","Immune Checkpoint Inhibitor Related Inflamamtory Arthritis",[187,188,189,190],"immune checkpoint inhibitor related inflamamtory arthritis","Inflammatory arthritis","rare auto-immune diseases","connective tissue disease","2026-03-30",{"date":193,"type":46},"2026-04-03",{"date":195,"type":46},"2026-03-27",{"date":197,"type":21},"2031-03-03",{"name":199,"class":53},"University Hospital, Brest",2,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":54},"100630766","palliative-and-supportive-care-to-help-people-with-arthritis-to-live-well-enrich-100630766","NCT07491939","Palliative and Supportive Care to Help People With Arthritis to Live Well (ENRICH)","Exploring Perspectives on Palliative and Supportive Care, to Inform Recommendations to Help People Live Well With Inflammatory Arthritis Throughout the Disease Course (ENRICH)","ENRICH","Inclusion Criteria:\n\n* Adults (\\> 18 years) with a diagnosis of arthritis (Rheumatoid, Psoriatic or Juvenile Idiopathic) or Axial Spondyloarthritis\n* able to understand and communicate in verbal and written English (or via an interpreter nominated by the participant or provided via an agency by the research team)\n* in receipt, or not in receipt of Palliative Care services\n* access to Microsoft Teams or a telephone\n* consent to sharing preferred contact details\n\nExclusion Criteria:\n\n* Cognitive impairment that impedes communication\n* non-English speaker (should an interpreter not be available).",{"count":210,"type":21},120,"Palliative Care (PC) focuses on maximising quality of life and care for patients and their families in the last 1000 days of life. Supportive Care (SC) is provided earlier in life for people with a long-term health condition.\n\nPeople living with inflammatory arthritis, (such as rheumatoid arthritis) can experience ongoing pain, stiffness, limitations in their joints, and intrusive fatigue. This impacts daily living activities and emotional well-being. People with inflammatory arthritis would value support to manage symptoms across the course of their disease. They would like PC healthcare professionals (HCPs) to understand their conditions better, so they can live well to the end of their lives.\n\nAims:\n\nThe investigators will explore the potential role of Palliative and Supportive Care (PSC) for people with inflammatory arthritis. The investigators will describe any unmet patient need. The investigators will develop clinical and research recommendations to help people with inflammatory arthritis live well over the course of their disease.\n\nPlan:\n\nThe investigators research will be conducted in three studies:\n\nStudy 1: The investigators will conduct 1:1 online interviews with people with inflammatory arthritis to understand how PSC is perceived by them, and what their views are on how PSC may support them to live well.\n\nStudy 2: The investigators will send an online survey to Rheumatologists, Primary Care, Community and PC HCPs, to understand:\n\n* if and how they work together currently;\n* their views on the role of PSC supporting people with inflammatory arthritis to live well.\n\nStudy 3: The investigators will conduct online focus groups with volunteers from Studies 1 and 2, representatives from relevant national charities\u002Forganisations, and people who commission health services. Together the group will discuss the research findings and agree:\n\n* what the gap in patient care is;\n* recommendations for future clinical practice and research;\n* the key areas of importance for patients which should be measured in future work",[25,213],"Palliative Care",[188,213],"2026-03-24",{"date":217,"type":46},"2026-03-25",{"date":219,"type":46},"2026-02-19",{"date":221,"type":21},"2027-04",{"name":223,"class":53},"Dorothy House Hospice",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":179,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":54},"100518997","phase-2-early-adalimumab-induction-for-immune-checkpoint-inhibitor-associated-inflammatory-arthritis-100518997","NCT06037811","Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial","Inclusion Criteria:\n\n* • Patients are deemed eligible for study participation if they meet all the following:\n\n  * Adult patients (age 18 or older)\n  * New (within the last 6 months prior to enrollment) inflammatory arthritis defined by any of the following at the time of screening (either on physical exam or by ultrasound) by a certified rheumatologist:\n* 1 or more swollen joints OR\n* 1 or more tenosynovitis OR\n* 1 or more enthesitis\n\n  * Arthritis onset with taking ICI therapy OR within 4 weeks of stopping ICI therapy including CTLA-4, PD-1, and PDL-1 inhibitors\n  * Initiation of ICI therapy must predate the onset of inflammatory arthritis\n  * Glucocorticoid dependence at any time before enrolment, defined by either:\n* Patients requiring prednisone at a dose of at least 10 mg daily (or equivalent) OR\n* Patients for whom at least 1 glucocorticoid taper failed to control the disease activity\n\n  * Negative tuberculosis (TB) status within the past 12 months (TB skin test or quantiferon) for the patients in the adalimumab group. If not available, the status should be confirmed within 6 months of enrollment in the study (adalimumab group only)\n  * Written informed consent provided by patient or power of attorney\n\nExclusion Criteria:\n\n* Patients are excluded if they meet any of the following:\n* Previous diagnosis of inflammatory arthritis or other rheumatic disease (prior to current acute episode)\n\n  * Including but not limited to: rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, systemic vasculitis, undifferentiated inflammatory arthritis, undifferentiated connective tissue disease\n* Tenosynovitis, synovitis or enthesitis attributed to another cause, fracture or acute gout\u002FCPPD flare.\n* Presence of a contraindication to adalimumab therapy\n\n  * Any of the following in the 7 days prior to initiation of adalimumab: positive tuberculin skin test (\\>5mm induration within 48 to 72 hours) or positive quantiferon, evidence of untreated active infection including fungal infection, opportunistic infection, hepatitis B\u002FC, or HIV\n  * Personal history of congestive heart failure\n  * Personal or family history of demyelinating neurologic disease\n* History of previous TNF inhibitor use\n* Current use of other disease modifying agents including: Chloroquine, Sulfasalazine, Azathioprine, 6-MP, and Leflunomide\n* Presence of a concomitant non-rheumatic irAE which required systemic immunosuppression within the past 3 months e.g. pneumonitis, hepatitis, colitis, scleritis, nephritis\n* Require chronic steroid treatment for adrenal insufficiency or another medical reason other than ir-IA\n* Pregnancy, breastfeeding or childbearing potential without practicing highly effective contraception.\n* Inability to participate in follow-up visits",{"count":232,"type":21},30,[234],"PHASE2","This study will examine the effectiveness of administering adalimumab as a treatment for patients in the early stages of steroid-dependent immune checkpoint Inhibitor associated inflammatory arthritis (ir-IA). Adalimumab (ADA) is a TNF inhibitor (TNFi) that is well established as a standard of care treatment for numerous types of inflammatory arthritis. It is hoped that adalimumab at the early stages of the ir-IA will reduce the symptoms and therefore reduce the need for steroids. This study is a pragmatic randomized clinical trial. Patients will be randomized 1:1 to each treatment group. To evaluate the steroid sparing effect of early induction six doses of Adalimumab will be administered to patients in the study treatment arm as compared to the usual standard of care of a predefined corticosteroid regimen and taper at 12 weeks administered in the control group.",[25,237],"Immune-related Adverse Event",[239,240,241],"Immune Checkpoint Inhibitor","Adalimumab","TNF-alpha inhibitor","2026-02-27",{"date":244,"type":46},"2026-03-03",{"date":246,"type":46},"2024-04-15",{"date":248,"type":21},"2028-12",{"name":250,"class":53},"Tom Appleton",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":179,"phases":263,"briefSummary":264,"conditions":265,"keywords":271,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":54},"100564678","dexa-bone-density-analysis-of-the-corehip-prosthesis-system-100564678","NCT06632301","DEXA Bone Density Analysis of the CoreHip® Prosthesis System","DEXA Bone Density Analysis to Analyze the Loading Concept of the CoreHip® Prosthesis","CODEX","Inclusion Criteria:\n\n* Unilateral hip osteoarthritis\n* Indication for CoreHip Standard hip stem according to preoperative planning\n* Written Informed Consent\n* Age 35-85 years\n* According to the assessment of the study doctor, the patient is therapy compliant and able to attend the follow-up visits\n\nExclusion Criteria:\n\n* Femoral neck fractures\n* Pregnancy\n* BMI \\> 35\n* History of femoral fracture or previous surgery on the same hip\n* Metabolic bone disease, use of steroids or other drugs affecting bone metabolism\n* Intraoperative bone cracks\n* Severe osteoarthritis of the contralateral hip\n* THA of the contralateral side or other event leading to restricted weight bearing during the study period","35 Years","85 Years",{"count":262,"type":21},40,[181],"The goal of this interventional post-market follow-up study is to evaluate radiological changes in the diaphyseal bone density (Gruen Zones 3 and 4) within 24 months postoperative in patients treated with CoreHip® primary cementless stem. The DEXA bone density analysis is used.",[266,267,268,25,269,270],"Primary Osteoarthritis","Cartilage Degeneration","Osteoarthritis, Hip","Osteonecrosis of Femoral Head","Traumatic Disorder",[272,273],"Total Hip Arthroplasty","DEXA Bone Density Analysis","2026-02-24",{"date":242,"type":46},{"date":277,"type":21},"2026-06",{"date":279,"type":21},"2028-09",{"name":281,"class":140},"Aesculap AG",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":179,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":200},"100557077","effect-of-a-self-management-intervention-for-patients-newly-diagnosed-with-inflammatory-arthritis-the-nisma-trial-100557077","NCT06533423","Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial","Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: Study Protocol for a Randomized Controlled NISMA Trial","Inclusion Criteria:\n\nPatients will be included if they are adults aged 18 years or older with one of the following conditions:\n\n* Rheumatoid Arthritis (RA) with ICD-10 codes: M05.3, M05.9, M05.8, M06.9 diagnosed within the last 6 months\n* Psoriatic Arthritis (PsA) with ICD-10 codes: M073.A, M073.B diagnosed within the last 6 months\n* Axial Spondyloarthritis (axSpA) with ICD-10 codes: M45.9, M46.1, M46.8, M46.9, diagnosed within the last 12 months, and has initiated biological treatment\n\nPatients with axSpA will have unique inclusion criteria due to NSAIDs being the first-line pharmacological treatment. For those effectively treated with NSAIDs and exercise, treatment is transitioned to their general practitioner. Therefore, only those who have initiated biological treatment will be included.\n\nExclusion Criteria:\n\nPatients will be excluded if they:\n\n* have insufficient language skills to discuss the topics in the intervention in Danish\n* are receiving chemo-therapy treatment for malignancies\n* are pregnant\n* have severe mental illness.","120 Years",{"count":291,"type":21},130,[181],"Background:\n\nIn patients newly diagnosed with inflammatory arthritis, a self-management intervention is anticipated to enhance self-management skills, thereby improving patient function, well-being, and survival. The primary objective of the trial is to investigate the short-term efficacy of the NISMA intervention and usual care, compared to usual care alone (control group), on self-management skills and techniques in patients newly diagnosed with inflammatory arthritis.\n\nMethod:\n\nThis study aims to test the efficacy of the \"Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention\" (NISMA) through a multicenter pragmatic randomized controlled trial (RCT). The trial will involve 130 patients newly diagnosed with IA from three Danish hospitals. Participants will be randomly assigned to either the NISMA intervention group or a control group receiving usual care. The NISMA intervention includes three mandatory individual sessions with a nurse, supplemented by two optional group sessions over 12 months.\n\nPrimary outcomes will be measured using the Health Education Impact Questionnaire (heiQ), focusing on the \"skill and technique acquisition\" domain. Secondary outcomes include other heiQ domains, quality of life, loneliness, physical function, pain intensity, pain, self-efficacy, anxiety and depression, fatigue, patient global assessment, disease activity, and medication adherence. Data will be collected at baseline, 12 months, and 18 months post-baseline.\n\nDiscussion:\n\nThis RCT will provide essential insights into the effectiveness of a targeted self-management intervention for patients newly diagnosed with IA. The NISMA intervention, developed following the Medical Research Council Framework for complex interventions, aims to improve self-management skills and overall QoL. By addressing the unique challenges faced by newly diagnosed patients, this study seeks to enhance the initial management of IA, aligning with the European Alliance of Associations for Rheumatology (EULAR) recommendations for self-management support. If successful, the NISMA intervention could represent a significant advancement in the non-pharmacological management of IA, offering a comprehensive, patient-centered approach that addresses both physical and psychological needs.",[25],[296,297,298,299,300,301,302],"self-management","rheumatoid arthritis","axial spondyloarthritis","psoriatic arthritis","newly diagnosed","heiQ","quality of life","2026-02-05",{"date":305,"type":46},"2026-02-09",{"date":307,"type":46},"2024-12-09",{"date":309,"type":21},"2028-05-30",{"name":311,"class":53},"Glostrup University Hospital, Copenhagen",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":179,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":54},"100545567","3d-dl-ozteo-in-the-detection-of-osseous-changes-in-patients-with-inflammatory-arthritis-100545567","NCT06383585","3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis","Evaluation of 3D DL oZTEo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis","Inclusion Criteria:\n\n* Adult patients ≥18 years of age\n* Hand radiographs performed within the past 3-6 months with imaging results available for analysis\n* Hand radiographs confirm the presence of bony erosions\n* Scheduled for a hand MRI as part of their routine clinical care at Mayo Clinic Rochester\n\nExclusion Criteria:\n\n\\- Less than18 years of age",{"count":320,"type":21},25,[181],"This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI.",[25],"2025-12-11",{"date":326,"type":46},"2025-12-17",{"date":328,"type":46},"2024-12-05",{"date":330,"type":21},"2026-12",{"name":332,"class":53},"Mayo Clinic",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":359},"100608298","a-multi-center-study-assessing-the-safety-and-efficacy-of-the-legion-medial-stabilized-ms-insert-in-patients-undergoing-a-total-knee-arthroplasty-tka-100608298","NCT07199738","A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)","Inclusion Criteria:\n\n1. A). Prospective Subjects: Subject needing primary Total Knee Arthroplasty (TKA) due to degenerative joint disease (primary diagnosis of osteoarthritis), post-traumatic arthritis or inflammatory arthritis.\n\n   OR\n\n   B). Retro-prospective Subjects: Subject has undergone primary TKA using the investigational product in the past 12 months to repair degenerative joint disease, post-traumatic arthritis or inflammatory arthritis and all the following conditions have been met:\n   * Pre-operative Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) has been obtained\n   * Post-operative radiographs have been obtained, or these can be collected prospectively in window per schedule of events\n   * 12-month post-operative KOOS JR have been obtained, or these can be collected prospectively in window per schedule of events\n2. Subject's treating clinician has decided the study device is suitable for the subjects TKA procedure and the study device is used in line with the applicable Instructions For Use (IFU) (listed in section 6).\n3. Subject agrees to consent and follow the prospective study visit schedule up to 10 years post-surgery (as defined in the study protocol and informed consent form) by signing the Independent Review Board (IRB)\u002FIndependent Ethics Committee (IEC) approved consent form.\n4. Subject is able to read, understand and communicate responses to Patient Reported Outcome Measure (PROM).\n5. Subject is 18-80 years old at the time of consent (inclusive).\n\nExclusion Criteria:\n\n1. Subject received revision TKA on the contralateral knee for a previously failed TKA, or Unicondylar Knee Arthroplasty (UKA).\n2. Subject has a Body Mass Index (BMI) ≥ 40 at pre-operative visit.\n3. Subject has ipsilateral hip arthritis resulting in flexion contracture of the hip joint.\n4. At the time of surgery, subject has one or more of the following arthroplasties that are not fully healed and\u002For well-functioning, in the opinion of the Investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; contralateral primary TKA or UKA.\n5. Subject has a condition that may interfere with the TKA survival or outcome (e.g., Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).\n6. Subject has a known allergy to one or more of the components of the study device.\n7. Any subject with hardware present in ipsilateral distal femur or proximal tibia.\n8. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.\n9. Subject is entered in another drug, biologic, or device study or has been treated with an investigational product in the past 30 days (30 days from operation\u002Fdosing).\n10. Subject, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study, ability to consent or complete the PROMs, including mental illness, drug or alcohol abuse.\n11. In the opinion of the Investigator, or site staff, Subject is at risk for lost to follow-up, or failure to return for scheduled visits.\n12. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures at the time of screening or the time of surgery.\n13. Subjects who have participated previously in this clinical trial and who have been withdrawn.\n14. Subject does not meet the indication or is contraindicated for TKA according to specific Smith+Nephew LEGION Knee System IFU.","80 Years",{"count":341,"type":21},144,"The purpose of this study is to assess the long-term safety and performance of the LEGION Medial Stabilized insert and to generate clinical evidence to support and maintain product registration in global markets.",[25,344,345],"Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis)","Post-traumatic Arthritis",[347,154,348,349],"Primary TKA","post-traumatic arthritis","inflammatory arthritis","2025-09-26",{"date":352,"type":46},"2025-09-30",{"date":354,"type":21},"2025-11",{"date":356,"type":21},"2036-12",{"name":358,"class":140},"Smith & Nephew, Inc.",6,{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":179,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":200},"100567304","comfi---a-combined-fatigue-intervention-100567304","NCT06666452","COMFI - a COMbined Fatigue Intervention","The Feasibility Test of a COMbined Fatigue Intervention (COMFI) for People With Inflammatory Athritis","COMFI","Inclusion Criteria:\n\n1. Current fatigue level (VAS-Fatigue: The VAS-fatigue has to be 60 or above.\n2. Must have experienced fatigue as a challenge for at least the last 3 months\n3. A rheumatologist-confirmed diagnosis of Rheumatoid Arthritis, Psoriatic Arthritis, or Spondyloarthritis\n4. The patient is in a stable phase regarding disease activity. This means no current plans to adjust pharmacological treatment, and no changes in treatment in the last 3 months (DMARDs or steroids) incl. steroid injections.\n5. Must be affiliated with the Danish Hospital of Rheumatic Diseases or Skaane University Hospital in Lund.\n6. Age ≥18 years.\n7. Must be able to speak and write Danish or Swedish well enough to participate in group discussions without an interpreter.\n8. The participant must be interested in actively participating and making changes to daily life to improve their condition.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Critical\u002Fserious illness:\n\n   * Diseases with an expected survival of \\\u003C 2 years (e.g., cancer)\n   * Heart failure with NYHA class 3 or 4\n   * Kidney failure with eGFR \\\u003C 30\n   * Severe anemia - hemoglobin ≤ 5.0 mmol\u002FL\n3. Clarification of known diseases, which must be well-treated or in remission:\n\n   * Diabetes: HbA1c \\>53 mmol\u002Fmol is excluded if dysregulated\n   * Thyroid disease: TSH: 0.4-4.0 mE\u002FL. Excluded if dysregulated\n4. A medical condition that would make the proposed interventions unsuitable\u002Fimpossible for group participation or hinder the ability to give informed consent:\n\n   * Unstable psychiatric illness\n   * Dementia or other severe cognitive problems\n   * Hearing loss\u002Fuse of hearing aids (it must be clarified how the person feels about being in a group setting)\n   * Other physical or mental conditions with the above effect\n5. Conditions that may be the primary cause of fatigue:\n\n   * Long-term effects after COVID-19\n   * Chronic fatigue syndrome\n6. Participation in another research project that could affect fatigue (WORK-ON, INSELMA, SPINCODE)\n7. Participation in the fatigue program for hospitalized patients or support in another way specifically related to fatigue\n8. The participant must not have a planned rehabilitation stay (e.g., Danish Rheumatism Hospital, Sano, Montebello) or another program elsewhere that works with fatigue\n9. If the participant cannot commit to attending on the scheduled dates in one of the two programs.",{"count":262,"type":21},[181],"Background: Inflammatory arthritis (IA) encompasses autoimmune rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Fatigue is highly prevalent in people with IA with 41-57% suffering from severe fatigue. Patients describe fatigue as overwhelming, unpredictable, challenging to manage, and affecting all areas of everyday life, including the ability to work. Studies have shown that interventions with physical activity or a cognitive behavioral approach can significantly reduce fatigue severity and\u002For impact in people with IA compared to usual care. To date, no studies have investigated the combined effect of CBA and PA on fatigue severity and impact in patients with IA. Therefore, the goal of this study is to test the feasibility of a newly developed fatigue intervention that combines a cognitive behavioral approach and physical activity (COMFI) in patients with inflammatory arthritis, who experience fatigue as a challenge in their everyday lives in Denmark and Sweden. The intervention will be tested in 4 groups (2 in Denmark and 2 in Sweden), and the participants will participate in 7 group sessions and 2 focusgroups interview in the evaluation.\n\nThe primary outcome for the participants is fatigue, measured through patient-reported outcomes at baseline, 3, 6, and 12 months after baseline.\n\nThis study will show if the intervention is feasible in practice and meaningful for the participants.",[27,372,373,25],"Psoriatic Arthritis (PsA)","Spondyloarthritis (SpA)",[375,376,377,378],"Fatigue","Intervention","cognitive behavioural approach","Physical activity","2025-08-14",{"date":381,"type":46},"2025-08-15",{"date":383,"type":46},"2024-10-01",{"date":385,"type":21},"2026-04",{"name":387,"class":53},"The Danish Center for Expertise in Rheumatology",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":179,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":54},"100594692","personalized-outreach-for-equitable-treatment-in-rheumatology-100594692","NCT07022756","Personalized Outreach for Equitable Treatment in Rheumatology","Personalized Outreach for Equitable Treatment in Rheumatology: A Randomized Controlled Trial of Patient Outreach and Honoraria in an Inner City Rheumatology Clinic","POET-Rheum","Inclusion Criteria:\n\n* Have a diagnosis of inflammatory arthritis secondary to an autoimmune rheumatic disease\n* Be attached to one of the Vancouver Coastal Health Community Health Centres for primary care\n* Be willing to attend in-person appointments at Pender Community Health Centre\n* Be at least 18 years of age and capable of consenting to participation\n* Be able to receive medical care in English.\n\nExclusion Criteria:\n\n* Have cognitive impairment or an untreated psychiatric condition that would severely impair ability to engage with outreach or treatment\n* Have no reasonably reliable method of contact (phone, email, social media, etc.)",{"count":397,"type":21},20,[181],"The primary goal of this study is to determine whether providing patient honoraria and\u002For outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.\n\nThe main question it aims to answer are:\n\n* Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic?\n* Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic?\n\nThe researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach.\n\nParticipants will:\n\n* Undergo randomization to receive honoraria or honoraria and outreach services together\n* Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals\n* Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition",[97,25,27,372,401],"Connective Tissue Disease",[403,25,404],"Rheumatology","Inner City Health","2025-07-01",{"date":407,"type":46},"2025-07-04",{"date":409,"type":21},"2025-07-02",{"date":277,"type":21},{"name":412,"class":53},"University of British Columbia",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":422,"targetDuration":424,"studyType":22,"phases":4,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":54},"100096125","prognostic-evaluation-of-inflammatory-polyarthritis-of-recent-onset-100096125","NCT00512239","Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset","Early Prediction of Patient-related and Radiological Outcomes in Patients With Recent-onset Inflammatory Polyarthritis (EPA) Using Established and Novel Independent Predictors","EUPA","Inclusion Criteria:\n\n* Early Rheumatoid arthritis\n* Early Inflammatory Arthritis\n\nExclusion Criteria:\n\n* Refusal or inability to consent\n* Infectious arthritis\n* Microcrystalline arthritis","90 Years",{"count":423,"type":21},1000,"10 Years","Inflammatory joint diseases are major causes of invalidity and morbidity. Rheumatoid arthritis (RA), the most frequent of chronic arthritides, affects close to 1% of the Canadian population. Direct and indirect costs of RA represent close to 1% of the gross national product. Recent evidence suggest that initiation of early (e.g., during the first 3-12 months of disease) aggressive treatment decreases both mortality and long term invalidity in RA and other chronic arthritides. However, a significant proportion of patients with early polyarthritis (EPA) have a benign evolution, even if they fulfill criteria for RA. On the contrary, most patients whose arthritis persist for more than 12 months have a progressive and destructive disease. Currently available clinical, serological and genetic markers of severity in arthritic patients perform poorly in EPA patients to identify those patients whose arthritis is likely to persist and thus who deserve an aggressive treatment.\n\nThe Investigators propose a prospective and longitudinal study to define the contribution of detection of rheumatoid arthritis-specific autoantibodies (RASA), either alone or in combination with other markers of severity, in the prognostic evaluation of patients presenting with EPA. Availability of such an effective serological tool to establish prognosis in individual patients would improve therapeutic decisions in clinical practice. The same prognostic tools would represent very powerful instruments to subset patients into more homogeneous groups in clinical trials, increasing their power.",[427,25],"Rheumatoid Arthritis",[429,430,431,432,433,434],"Early Rheumatoid Arthritis","Early inflammatory arthritis","Biomarkers","Autoantibodies","Anti-Sa antibodies","Anti-CCP antibodies","2025-03-24",{"date":437,"type":46},"2025-03-25",{"date":439,"type":46},"1998-07",{"date":441,"type":21},"2035-12",{"name":443,"class":53},"Gilles Boire",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":179,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":4},"100528547","the-active-trial-a-prospective-randomised-control-trial-of-the-h1-implant-versus-total-hip-replacement-100528547","NCT06162195","The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement","ACTIVE","Inclusion Criteria:\n\n* Patient requires unilateral primary hip arthroplasty due to primary osteoarthritis, osteoarthritis secondary to e.g. trauma, avascular necrosis or developmental hip dysplasia, or inflammatory arthritis.\n* Patient is willing to comply with study requirements.\n* Patient plans to be available through 10 years postoperative follow-up.\n\nExclusion Criteria:\n\n* Patient has a BMI greater than 40 kg\u002Fm².\n* Patient has active infection or sepsis (treated or untreated).\n* Patient has insufficient bone stock at the hip (\\>1\u002F3 necrosis of the femoral head or large and multiple cysts) or in general as in severe osteopenia or osteoporosis (t-score \\\u003C -2.5 as measured with BMD).\n* Patient is not skeletally mature.\n* Patient meets the contraindication criteria of the control device.\n* Patient already has another lower limb arthroplasty or arthrodesis or will require a further lower limb arthroplasty or arthrodesis within the subsequent 2 years.\n* Patient lacks capacity to consent.\n* Patient is unable to understand the native language of the country where their procedure is taking place",{"count":452,"type":21},200,[181],"The goal of this randomised controlled trial is to compare the success of two types of hip replacement in patients with hip arthritis. The main question it aims to answer is whether a new type of hip replacement (called a hip resurfacing) can be as successful as an existing hip replacement (called a total hip replacement). Patients will be given either the new hip resurfacing or the existing total hip replacement and researchers will compare their function, complication rate and physical activity.",[268,25],[457,458,459],"Hip","Resurfacing","Ceramic","2023-12-06",{"date":462,"type":46},"2023-12-08",{"date":464,"type":21},"2024-09",{"date":466,"type":21},"2035-04",{"name":468,"class":140},"Embody Orthopaedic Limited",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":476,"targetDuration":424,"studyType":22,"phases":4,"briefSummary":478,"conditions":479,"keywords":489,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":500},"100494573","the-kinematx-midcarpal-total-wrist-arthroplasty-registry-100494573","NCT05719935","The KinematX Midcarpal Total Wrist Arthroplasty Registry","The KinematX Midcarpal Total Wrist Arthroplasty: A Multicenter Prospective Registry of Clinical and Patient-Reported Outcomes","Inclusion Criteria:\n\n* one of the following diagnoses and planned (or previously completed) total wrist arthroplasty with the KinematX total wrist:\n\n  * osteoarthritis or post-traumatic arthritis\n  * scapholunate advanced collapse (SLAC\u002FSNAC wrist),\n  * inflammatory arthritis (rheumatoid, psoriatic, other),\n  * crystalline advanced collapse (SCAC),\n  * STT advanced collapse (STTAC),\n  * ulnar translocation,\n  * Kienbӧck disease,\n  * radial malunion\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* \\>85 years of age\n* Prisoners\n* Children\n* Pregnant women\n* Contraindications to receiving the KinematX:\n\n  * Local, distant or systematic acute or chronic soft tissue or bony infection\n  * Physiologically or psychologically compromised patient\n  * Active wrist synovitis or severe carpal bone erosion\n  * Suspected or documented metal allergy or intolerance\n  * Insufficient extensor tendons\n  * Inadequate skin, bone, neural or vascular status\n  * Severe carpal bone malalignment, displacement, absorption, neoplastic, or carpal bone pathology\n  * Sepsis\n  * Osteomyelitis\n  * Uncontrolled\u002Funtreated osteoporosis or metabolic bone disease\n  * Metabolic or endocrinologic bone disorders\n  * Osteomalacia\n  * Distant foci of infections which may spread to the implant site\n  * Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram",{"count":477,"type":21},50,"The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study.\n\nThe main questions it aims to answer are:\n\n* What is the range of motion (flexion, extension, radial, ulnar, grip and pinch strength) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant.\n* What are the patient reported outcomes (PROMIS, PRWE, HSS wrist expectations) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant.\n* How do range of motion and patient reported outcomes change over the 10 years after total wrist replacement surgery?\n\nParticipants will be followed according to standard of care and preoperative and post-operative information for up to 10 years after surgery will be collected and entered into an electronic data base. Patients are eligible to enroll into the registry before or after they have had their wrist replacement surgery.",[480,481,482,483,484,485,486,487,25,154,488],"Scapholunate Advanced Collapse (SLAC)","Scapholunate Crystalline Advanced Collapse (SCAC)","Scaphoid, Trapezium, and Trapezoid Advanced Collapse (STTAC)","Carpal Tunnel Syndrome (CTS)","Kienbock's Disease of Adults","Radial Malunion","Ulnar Translocation","Post Traumatic Arthritis","Scaphoid Non-union Advanced Collapse (SNAC)",[490,491],"Total wrist replacement","Total wrist arthroplasty","2023-11-13",{"date":494,"type":46},"2023-11-15",{"date":496,"type":46},"2021-04-26",{"date":441,"type":21},{"name":499,"class":140},"Extremity Medical",4]